F Zoulim

Summary

Country: France

Publications

  1. ncbi request reprint Evolution of hepatitis B viral load and viral genome sequence during adefovir dipivoxil therapy
    B Werle
    INSERM Unit 271, Albert Thomas, Lyon, France
    J Viral Hepat 11:74-83. 2004
  2. ncbi request reprint Analysis of HCV co-infection with occult hepatitis B virus in patients undergoing IFN therapy
    E Khattab
    INSERM Unit 271, 151 Cours Albert Thomas, 69424 Lyon Cedex 03, France
    J Clin Virol 33:150-7. 2005
  3. ncbi request reprint Glucosidase inhibitors as antiviral agents for hepatitis B and C
    David Durantel
    INSERM U271, Laboratoire des virus hépatiques et pathologies associées, 151 Cours Albert Thomas, Lyon F 69424, France
    Curr Opin Investig Drugs 8:125-9. 2007
  4. ncbi request reprint Hepatitis B virus genetic variability and evolution
    Alan Kay
    INSERM, U871, Physiopathologie moléculaire et nouveaux traitements des hépatites virales, 151 Cours A Thomas, Lyon F 69424, France
    Virus Res 127:164-76. 2007
  5. ncbi request reprint Antiviral therapy of chronic hepatitis B: prevention of drug resistance
    Claire Fournier
    Hospices Civils de Lyon, Hotel Dieu, Service d Hepato Gastroenterologie, 69002 Lyon, France
    Clin Liver Dis 11:869-92, ix. 2007
  6. pmc Meta-analyses of FibroTest diagnostic value in chronic liver disease
    Thierry Poynard
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Universite Paris VI, CNRS ESA 8067 Paris, France
    BMC Gastroenterol 7:40. 2007
  7. ncbi request reprint Entecavir: a new treatment option for chronic hepatitis B
    Fabien Zoulim
    INSERM Unit 271, Liver Department, Hotel Dieu Hospital, Hospices Civils de Lyon, Universite Lyon 1, 151 Cours Albert Thomas, 69003 Lyon, France
    J Clin Virol 36:8-12. 2006
  8. ncbi request reprint Antiviral-resistant hepatitis B virus: can we prevent this monster from growing?
    F Zoulim
    INSERM, U871, 69003 Lyon, France
    J Viral Hepat 14:29-36. 2007
  9. ncbi request reprint Combination of nucleoside analogues in the treatment of chronic hepatitis B virus infection: lesson from experimental models
    Fabien Zoulim
    INSERM U271, 151 Cours Albert Thomas, 69003 Lyon, France
    J Antimicrob Chemother 55:608-11. 2005
  10. ncbi request reprint New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA
    Fabien Zoulim
    INSERM Unit 271, 151 Cours Albert Thomas, 69003 Lyon, France
    J Hepatol 42:302-8. 2005

Detail Information

Publications125 found, 100 shown here

  1. ncbi request reprint Evolution of hepatitis B viral load and viral genome sequence during adefovir dipivoxil therapy
    B Werle
    INSERM Unit 271, Albert Thomas, Lyon, France
    J Viral Hepat 11:74-83. 2004
    ..Our results showed that ADV administration for 48-72 weeks effectively suppresses HBV replication without the emergence of resistant viral mutants...
  2. ncbi request reprint Analysis of HCV co-infection with occult hepatitis B virus in patients undergoing IFN therapy
    E Khattab
    INSERM Unit 271, 151 Cours Albert Thomas, 69424 Lyon Cedex 03, France
    J Clin Virol 33:150-7. 2005
    ..Our aim was, therefore, to assess the prevalence and clinical consequences of occult HBV infection in chronic hepatitis C patients undergoing antiviral therapy...
  3. ncbi request reprint Glucosidase inhibitors as antiviral agents for hepatitis B and C
    David Durantel
    INSERM U271, Laboratoire des virus hépatiques et pathologies associées, 151 Cours Albert Thomas, Lyon F 69424, France
    Curr Opin Investig Drugs 8:125-9. 2007
    ..This review will discuss HBV and HCV morphogenesis, with a particular focus on the role of N-glycosylation for viral protein folding and assembly, and will present the antiviral properties of glucosidase inhibitors...
  4. ncbi request reprint Hepatitis B virus genetic variability and evolution
    Alan Kay
    INSERM, U871, Physiopathologie moléculaire et nouveaux traitements des hépatites virales, 151 Cours A Thomas, Lyon F 69424, France
    Virus Res 127:164-76. 2007
    ..Also, human intervention in the form of mass vaccination and antiviral treatment will reduce the burden of HBV-related liver disease but may also be accelerating evolution of the virus...
  5. ncbi request reprint Antiviral therapy of chronic hepatitis B: prevention of drug resistance
    Claire Fournier
    Hospices Civils de Lyon, Hotel Dieu, Service d Hepato Gastroenterologie, 69002 Lyon, France
    Clin Liver Dis 11:869-92, ix. 2007
    ..Because of the variability of the HBV genome, such long-term treatments are associated with the emergence of resistant viral strains, which may compromise the initial clinical benefit of the treatment...
  6. pmc Meta-analyses of FibroTest diagnostic value in chronic liver disease
    Thierry Poynard
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Universite Paris VI, CNRS ESA 8067 Paris, France
    BMC Gastroenterol 7:40. 2007
    ....
  7. ncbi request reprint Entecavir: a new treatment option for chronic hepatitis B
    Fabien Zoulim
    INSERM Unit 271, Liver Department, Hotel Dieu Hospital, Hospices Civils de Lyon, Universite Lyon 1, 151 Cours Albert Thomas, 69003 Lyon, France
    J Clin Virol 36:8-12. 2006
    ..The availability of entecavir as a new treatment option is providing clinicians more choice to keep both viral replication and liver disease under control. This provides new hope for improved treatment concepts for chronic HBV infection...
  8. ncbi request reprint Antiviral-resistant hepatitis B virus: can we prevent this monster from growing?
    F Zoulim
    INSERM, U871, 69003 Lyon, France
    J Viral Hepat 14:29-36. 2007
    ..Clinical studies are ongoing to determine the best strategy to prevent or delay antiviral drug resistance and of its impact on liver disease...
  9. ncbi request reprint Combination of nucleoside analogues in the treatment of chronic hepatitis B virus infection: lesson from experimental models
    Fabien Zoulim
    INSERM U271, 151 Cours Albert Thomas, 69003 Lyon, France
    J Antimicrob Chemother 55:608-11. 2005
    ....
  10. ncbi request reprint New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA
    Fabien Zoulim
    INSERM Unit 271, 151 Cours Albert Thomas, 69003 Lyon, France
    J Hepatol 42:302-8. 2005
  11. ncbi request reprint Antiviral therapy of chronic hepatitis B: can we clear the virus and prevent drug resistance?
    Fabien Zoulim
    INSERM U271, Lyon, France
    Antivir Chem Chemother 15:299-305. 2004
    ....
  12. pmc Emerging drugs for hepatitis B
    Fabien Zoulim
    INSERM, U871, 151 Cours Albert Thomas, 69424 Lyon Cedex 03, France
    Expert Opin Emerg Drugs 12:199-217. 2007
    ..Discovery of new antiviral drugs and design of new treatment strategies are, therefore, needed to manage this disease, which is still the main cause of cirrhosis and hepatocellular carcinoma worldwide...
  13. ncbi request reprint Assessment of treatment efficacy in HBV infection and disease
    Fabien Zoulim
    INSERM Unit 271, 151 Cours Albert Thomas, 69003 Lyon, France
    J Hepatol 44:S95-9. 2006
    ....
  14. ncbi request reprint Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection
    Fabien Zoulim
    INSERM Unit 271, Insitut Universitaire de France, 151 Cours Albert Thomas, 69003 Lyon, France
    Antiviral Res 64:1-15. 2004
    ..The mechanism of HBV resistance to nucleoside analogs are described as well as the concept for multiple drug therapy and combination with immunostimulatory approaches...
  15. ncbi request reprint Hepatitis B virus resistance to antivirals: clinical implications and management
    Fabien Zoulim
    INSERM U 271 and Liver Department, Institut Universitaire de France, 151 Cours Albert Thomas, F 69003 Lyon, France
    J Hepatol 39:S133-8. 2003
  16. ncbi request reprint [Definitions of resistance to analogue antiviral drugs in the treatment of chronic hepatitis B]
    Fabien Zoulim
    INSERM U271, Laboratoire des virus hépatiques et pathologies associées, 151 Cours Albert Thomas, 69424 Lyon Cedex 03, France
    Gastroenterol Clin Biol 30:3S9-11. 2006
  17. ncbi request reprint Clinical consequences of hepatitis C virus infection
    F Zoulim
    INSERM U 271, 151 Cours Albert Thomas, 69424 Lyon Cedex 03, France
    Rev Med Virol 13:57-68. 2003
    ..A better knowledge of the pathobiology of HCV and its clinical consequences will be important for developing better treatment strategies to cure HCV infection and extrahepatic manifestations...
  18. ncbi request reprint Animal models for the study of HBV infection and the evaluation of new anti-HBV strategies
    F Zoulim
    INSERM U271 and Liver Department, Lyon, France
    J Gastroenterol Hepatol 17:S460-3. 2002
    ..Our aim was to evaluate the anti-HBV activity of a novel L-nucleoside analog, 2',3'-dideoxy-2',3'-didehydro-beta-L-5-fluorocytidine (beta-L-Fd4C), in study models of HBV infection...
  19. ncbi request reprint Antiviral therapy of chronic hepatitis B
    Fabien Zoulim
    Liver Department, Hotel Dieu, INSERM Unit 271, 151 Cours Albert Thomas, 69003 Lyon, France
    Antiviral Res 71:206-15. 2006
    ..However, the development of new antiviral agents is rapidly improving the offing of therapy of chronic hepatitis B. These new therapeutic advances are reviewed in this manuscript...
  20. pmc Antiviral activity of beta-L-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine in woodchucks chronically infected with woodchuck hepatitis virus
    F Le Guerhier
    INSERM Unit 271, 69003 Lyon, 69008 Lyon, France
    Antimicrob Agents Chemother 45:1065-77. 2001
    ..These results indicate that beta-L-Fd4C exhibits a more potent antiviral effect than lamivudine in the WHV model but was not able to eradicate CCC DNA and infected cells from the liver at the dosage and with the protocol used...
  21. pmc In vitro characterization of the anti-hepatitis B virus activity and cross-resistance profile of 2',3'-dideoxy-3'-fluoroguanosine
    A C Jacquard
    INSERM U271, 151 Cours Albert Thomas, 69424 Lyon Cedex 03, France
    Antimicrob Agents Chemother 50:955-61. 2006
    ..Furthermore, our results provide the rationale for further clinical evaluation of FLG in the treatment of drug-resistant virus infection and in the setting of combination therapy to prevent or delay drug resistance...
  22. ncbi request reprint High incidence of hepatitis B infections among chronic hepatitis cases of unknown aetiology
    I Chemin
    INSERM U271, Lyon, France
    J Hepatol 34:447-54. 2001
    ..We selected sera from 50 patients with chronic hepatitis of unknown aetiology who were enrolled in this follow-up study whose aim is to gain insight into the possible role of viruses and to define potential clinical outcomes...
  23. doi request reprint Hepatitis B virus: from diagnosis to treatment
    P Deny
    INSERM, U871, 69003, Lyon, France
    Pathol Biol (Paris) 58:245-53. 2010
    ....
  24. ncbi request reprint The SATE pronucleotide approach applied to acyclovir: part II. Effects of bis(SATE)phosphotriester derivatives of acyclovir on duck hepatitis B virus replication in vitro and in vivo
    O Hantz
    INSERM U 271, Lyon, France
    Antiviral Res 40:179-87. 1999
    ..These findings demonstrate the potential of SATE pronucleotides of ACV as anti-HBV agents...
  25. pmc Effect of a combination of clevudine and emtricitabine with adenovirus-mediated delivery of gamma interferon in the woodchuck model of hepatitis B virus infection
    A C Jacquard
    INSERM U271, 151 Cours Albert Thomas, 69003 Lyon, France
    Antimicrob Agents Chemother 48:2683-92. 2004
    ..However, no extra benefit of adding IFN-gamma gene transduction to the L-FMAU/FTC combination could be detected...
  26. ncbi request reprint Duck hepatitis B virus polymerase gene mutants associated with resistance to lamivudine have a decreased replication capacity in vitro and in vivo
    B Seigneres
    INSERM Unit 271, Lyon, France
    J Hepatol 34:114-22. 2001
    ..To study the biology of these mutants, we analyzed their replication capacity in the duck hepatitis B virus (DHBV) infection...
  27. pmc A prospective study of the evolution of lamivudine resistance mutations in patients with chronic hepatitis B treated with lamivudine
    F Zoulim
    INSERM U271, Lyon, France
    J Viral Hepat 13:278-88. 2006
    ..This prospective cohort study identified lamivudine-resistant mutations emerging in 22% of subjects, yearly, which were apparently not associated with clinical aggravation over the study period...
  28. ncbi request reprint Occult HBV infection may represent a major risk factor of non-response to antiviral therapy of chronic hepatitis C
    S Mrani
    INSERM U271, 151 Cours A Thomas, 69003 Lyon, France
    J Med Virol 79:1075-81. 2007
    ..Such an occult HBV co-infection is associated with more severe liver disease, higher HCV viral load and decreased response to antiviral therapy irrespective of HCV genotypes...
  29. doi request reprint In vivo infectivity of liver extracts after resolution of hepadnaviral infection following therapy associating DNA vaccine and cytokine genes
    F Saade
    Universite de Lyon, Lyon, Lyon, France
    J Viral Hepat 20:e56-65. 2013
    ....
  30. ncbi request reprint Evolution of hepatitis C virus genome in chronically infected patients receiving ribavirin monotherapy
    F Querenghi
    INSERM Unit 271, 151 Cours Albert Thomas, 69003 Lyon, France
    J Viral Hepat 8:120-31. 2001
    ..Altogether these results suggest that ribavirin may not exhibit a direct antiviral effect, but may trigger a favourable response to interferon by modulating the immune response against HCV...
  31. ncbi request reprint Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient
    Stephanie Villet
    INSERM U271, Laboratoire des virus hépatiques et pathologies associées, 151 Cours Albert Thomas, 69424 Lyon Cedex 03, France
    Gastroenterology 131:1253-61. 2006
    ....
  32. ncbi request reprint [New virologic tests and their application in management of chronic hepatitis B]
    Fabien Zoulim
    Service d hépatologie et gastro entérologie, Hotel Dieu, Unité 271, INSERM, Lyon
    Presse Med 35:317-26. 2006
    ..Appropriate management of chronic hepatitis B must rely not only on the standard serologic markers but also on tests that quantify viral load and on the study of viral genome variability according to clinical situation...
  33. pmc Effects of pyrimidine and purine analog combinations in the duck hepatitis B virus infection model
    Beatrice Seigneres
    INSERM Unit 271, 69003 Lyon, France
    Antimicrob Agents Chemother 47:1842-52. 2003
    ..However, no viral clearance from the liver was observed, suggesting that the enhanced antiviral effect of this combination was not sufficient for cccDNA suppression and HBV eradication from infected cells...
  34. pmc In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants
    M N Brunelle
    INSERM, U871, 151 Cours Albert Thomas, 69424 Lyon Cedex 03, France
    Antimicrob Agents Chemother 51:2240-3. 2007
    ..Most drug-resistant mutants, including multidrug-resistant strains, remained sensitive to tenofovir and PMEO-DAPym. Therefore, the latter molecule deserves further evaluation for the treatment of HBV infection...
  35. doi request reprint Proficiency of transient elastography compared to liver biopsy for the assessment of fibrosis in HIV/HBV-coinfected patients
    P Miailhes
    Hospices Civils de Lyon, Hopital Hotel Dieu, Service d Hepatogastroenterologie, Lyon, France
    J Viral Hepat 18:61-9. 2011
    ..In HIV/HBV-coinfected patients, most of them with normal ALT under antiretroviral treatment including HBV active drugs, TE was proficient in discriminating moderate to severe fibrosis from minimal liver disease...
  36. ncbi request reprint Initial amplification of duck hepatitis B virus covalently closed circular DNA after in vitro infection of embryonic duck hepatocytes is increased by cell cycle progression
    C Borel
    , Lyon, France
    Hepatology 34:168-79. 2001
    ..Taken together, these results show that hepatocyte proliferation may positively regulate the initial amplification of CCC DNA of avian hepadnaviruses, and may explain why mitosis is not necessarily associated with loss of CCC DNA...
  37. ncbi request reprint Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir
    Marie Noëlle Brunelle
    INSERM U271, Laboratoire des virus hépatiques et pathologies associées, Lyon, France
    Hepatology 41:1391-8. 2005
    ..However, other nucleos(t)ide analogs in development showed an antiviral activity against this multiresistant strain in vitro. This provides a rationale for the clinical evaluation of de novo combination therapies...
  38. doi request reprint Sexually transmitted HCV infection and reinfection in HIV-infected homosexual men
    L Cotte
    Service d hépatologie et de sida, Hotel Dieu, Hospices Civils de Lyon, 1, Place de l Hopital, 69002 Lyon, France INSERM, U871, 69003 Lyon, France
    Gastroenterol Clin Biol 33:977-80. 2009
    ..Therefore, sexual HCV reinfection can occur in homosexual men having unprotected sex and "serosorting" should be considered a risk factor for the sexual transmission of HCV...
  39. pmc Inhibitory effect of adefovir on viral DNA synthesis and covalently closed circular DNA formation in duck hepatitis B virus-infected hepatocytes in vivo and in vitro
    Julien Delmas
    INSERM Unit 271, 69003 Lyon, France
    Antimicrob Agents Chemother 46:425-33. 2002
    ..Taken together, our results demonstrate that adefovir is a potent inhibitor of DHBV replication that inhibits CCC DNA amplification but does not effectively prevent the formation of CCC DNA from incoming viral genomes...
  40. ncbi request reprint Inhibitory activity of dioxolane purine analogs on wild-type and lamivudine-resistant mutants of hepadnaviruses
    Beatrice Seigneres
    INSERM Unit 271, Lyon, France
    Hepatology 36:710-22. 2002
    ..In conclusion, the unique mechanism of action of these new inhibitors warrants further evaluation in experimental models to determine their capacity to delay or prevent the selection of drug resistant mutants...
  41. ncbi request reprint Suboptimal response to adefovir dipivoxil therapy for chronic hepatitis B in nucleoside-naive patients is not due to pre-existing drug-resistant mutants
    Sandra Carrouée-Durantel
    INSERM, U871, 69003 Lyon, France
    Antivir Ther 13:381-8. 2008
    ..After 1 year of therapy, a median 3.5-4.0 log10 decrease in viral load is observed. Our aim was to characterize the different profiles of response to ADV in relation to the in vitro susceptibility of viral strains to ADV...
  42. doi request reprint Persistence of the hepatitis B virus covalently closed circular DNA in HepaRG human hepatocyte-like cells
    O Hantz
    INSERM, U871, 69003 Lyon, France
    J Gen Virol 90:127-35. 2009
    ..In conclusion, HBV infection in differentiated HepaRG cells is characterized by long-term persistence without a key feature of hepadnaviruses, the so-called 'CCC DNA amplification' described in the duck hepatitis B model...
  43. doi request reprint Hepatitis B virus induced hepatocellular carcinoma
    I Chemin
    INSERM, U871, 69003 Lyon, France
    Cancer Lett 286:52-9. 2009
    ..There are evidences that occult HBV is a risk factor for the development of HCC and that the potential mechanisms whereby overt HBV might induce tumour formation are mostly maintained...
  44. pmc Selective inhibition of the duck hepatitis B virus by a new class of tetraazamacrocycles
    O Hantz
    Unité de Recherche sur les Hépatites, le SIDA et les Retrovirus Humains, Institut National de la Santé et de la Recherche Médicale U271, Lyon, France
    Antimicrob Agents Chemother 41:2579-81. 1997
    ..Three of the four tested compounds were able to selectively inhibit DHBV replication by acting at an early step of the hepadnavirus infection but were associated with significant toxicity...
  45. pmc Rolling circle amplification, a powerful tool for genetic and functional studies of complete hepatitis B virus genomes from low-level infections and for directly probing covalently closed circular DNA
    Séverine Margeridon
    INSERM, U871, Lyon, France
    Antimicrob Agents Chemother 52:3068-73. 2008
    ..It can also be used to probe HBV cccDNA, the crucial intermediate in viral persistence and the archive of resistance mutations...
  46. doi request reprint New approaches to the management of hepatitis C in haemophilia in 2012
    F Zoulim
    Hepatology Department, Hospices Civils de Lyon, University of Lyon, INSERM U1052, Lyon, France
    Haemophilia 18:28-33. 2012
    ..These advances provide new hope in the management of chronic hepatitis C, including patients with hereditary bleeding disorders...
  47. ncbi request reprint Therapy of chronic hepatitis B virus infection: inhibition of the viral polymerase and other antiviral strategies
    F Zoulim
    INSERM Unit 271, Lyon, France
    Antiviral Res 44:1-30. 1999
    ..The search for new viral targets is therefore mandatory to design combination strategies to prevent the emergence of resistant mutants and eventually clear viral infection...
  48. ncbi request reprint Evaluation of novel strategies to combat hepatitis B virus targetting wild-type and drug-resistant mutants in experimental models
    F Zoulim
    INSERM Unit 271, Lyon, France
    Antivir Chem Chemother 12:131-42. 2001
    ..Combination of these new anti-HBV agents with DNA based immunization may prove useful to eradicate viral infection...
  49. doi request reprint Initiation of hepatitis B virus genome replication and production of infectious virus following delivery in HepG2 cells by novel recombinant baculovirus vector
    J Lucifora
    INSERM, U871, 151 Cours Albert Thomas, 69003 Lyon, France
    J Gen Virol 89:1819-28. 2008
    ..In conclusion, an improved cell-culture system was established for the transduction of replication-competent HBV genomes. This will be useful for future studies of the fitness of HBV mutants...
  50. doi request reprint [Combination therapy in chronic hepatitis B]
    C Fournier
    INSERM, U871, 151, cours Albert Thomas, 69003 Lyon, France
    Gastroenterol Clin Biol 32:S42-9. 2008
    ..However, de novo combination is recommended in patients whose liver functions cannot tolerate treatment failure, and in patients with a high risk of developing viral resistance because of a complex viral quasi-species prior to therapy...
  51. ncbi request reprint Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection
    C Bain
    Institut National de la Sante et de la Recherche Medicale, Lyon, France
    Gastroenterology 120:512-24. 2001
    ..During natural infection with hepatitis C virus (HCV), the interactions between the virus and DC may contribute to viral persistence, a general feature of HCV infection...
  52. ncbi request reprint Inhibitory effect of the combination of CpG-induced cytokines with lamivudine against hepatitis B virus replication in vitro
    Isabelle E Vincent
    INSERM U871, Lyon, France
    Antivir Ther 14:131-5. 2009
    ..Our aim was to establish the proof of concept of the antiviral benefit of combining a nucleoside analogue with CpG-induced cytokines on HBV replication in vitro...
  53. doi request reprint Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure
    Stephanie Villet
    INSERM U871, Laboratoire des virus hépatiques et pathologies associées, 151 Cours Albert Thomas, Lyon Cedex 03, France
    J Hepatol 48:747-55. 2008
    ..In this study, we characterized the main variants harboring the rtA181T/V mutation isolated from 10 consecutive patients who developed lamivudine and/or adefovir resistance...
  54. ncbi request reprint Antiviral effect of adefovir in combination with a DNA vaccine in the duck hepatitis B virus infection model
    Franck Le Guerhier
    INSERM Unit 271, 151 Cours Albert Thomas, 69003 Lyon, France
    J Hepatol 38:328-34. 2003
    ..We used the duck HBV (DHBV) infection model to evaluate the efficacy of the combination of adefovir with DNA-immunization by comparison with the respective monotherapies...
  55. ncbi request reprint Benefit of sustained virological response to combination therapy on graft survival of liver transplanted patients with recurrent chronic hepatitis C
    Thierry Bizollon
    Hotel Dieu, Lyon, France
    Am J Transplant 5:1909-13. 2005
    ..009). No difference in patient survival was observed in the two groups. In conclusion, this study shows that HCV eradication has a positive impact on graft survival...
  56. doi request reprint Pathobiology of HBV mutants and clinical impact for treatment monitoring
    Si Nafa Si Ahmed
    INSERM, U871, 69003 Lyon, France
    Expert Rev Anti Infect Ther 7:309-20. 2009
    ..Clinical experience shows that an optimal management of antiviral therapy allows the control of viral replication in the majority of patients in whom liver disease progression is halted...
  57. doi request reprint Evolution of glomerular filtration rate in HIV-infected, HIV-HBV-coinfected and HBV-infected patients receiving tenofovir disoproxil fumarate
    P Pradat
    Hospices Civils de Lyon, Hopital de la Croix Rousse, Service d Hepatologie, Lyon, France INSERM U1052, Lyon, France Université Lyon 1, Lyon, France
    J Viral Hepat 20:650-7. 2013
    ..Regular follow-up of renal function, especially tubular function is recommended during TDF therapy. ..
  58. pmc Long term histological improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplanted patients with hepatitis C virus recurrence
    T Bizollon
    Hepatology Unit, Hotel Dieu, Lyon 69288, and INSERM U 271, 151 Cours A Thomas, Lyon 69424, France
    Gut 52:283-7. 2003
    ..This study examined the long term biochemical, virological, and histological outcome in transplanted patients with recurrent chronic hepatitis who had a sustained virological response to antiviral therapy...
  59. ncbi request reprint Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy
    Bettina Werle-Lapostolle
    INSERM Unit 271, 151 Cours Albert Thomas, 69003 Lyon, France
    Gastroenterology 126:1750-8. 2004
    ..The aim of this study was to develop a sensitive and specific assay for quantifying cccDNA in biopsy samples from chronic hepatitis B patients during different natural history phases and in patients undergoing antiviral therapy...
  60. ncbi request reprint Detection of hepatitis B virus resistance to antivirals
    F Zoulim
    INSERM Unit 271, 151 Cours Albert Thomas, 69003, Lyon, France
    J Clin Virol 21:243-53. 2001
    ....
  61. ncbi request reprint [Vaccination against hepatitis B virus: current data]
    F Zoulim
    Service d Hepatogastroenterologie, l Hôpital Hôtel Dieu, Lyon, France
    Med Trop (Mars) 59:503-7. 1999
    ..The recently revised benefit-to-risk ratio remains highly favorable for vaccination. Current data indicates that the policy of mass vaccination of the population should be pursued...
  62. ncbi request reprint [Treatment of patients with chronic hepatitis C who relapsed or did not respond to a previous treatment]
    Fabien Zoulim
    Hotel Dieu, Place de l Hopital, 69002 Lyon, INSERM U271, 151, cours Albert Thomas, 69003 Lyon
    Gastroenterol Clin Biol 26:B225-30. 2002
  63. ncbi request reprint Characterization of two hepatitis B virus populations isolated from a hepatitis B surface antigen-negative patient
    Damien Jeantet
    U271 INSERM, 151 Cours Albert Thomas, Lyon Cedex 03, France
    Hepatology 35:1215-24. 2002
    ..In conclusion, the cryptic nature of this double HBV infection is characterized by the predominance of the replication-deficient genotype D virus over the replication-competent genotype A virus...
  64. ncbi request reprint In vitro models for studying hepatitis B virus drug resistance
    Fabien Zoulim
    INSERM Unit 271, Institut Universitaire de France, Lyon, France
    Semin Liver Dis 26:171-80. 2006
    ..The different in vitro models for the study of HBV resistance include enzymatic and cell-based assays. Their relevance for the analysis of viral fitness, drug susceptibility, and cross-resistance is also reviewed...
  65. doi request reprint DNA vaccination in combination or not with lamivudine treatment breaks humoral immune tolerance and enhances cccDNA clearance in the duck model of chronic hepatitis B virus infection
    Alexandre Thermet
    INSERM, Unit 871, F 69424 Lyon, France
    J Gen Virol 89:1192-201. 2008
    ..These results also highlight the importance of antiviral drug potency and an effective DNA immunization protocol for the design of therapeutic vaccines against chronic hepatitis B...
  66. doi request reprint DNA methylation of hepatitis B virus (HBV) genome associated with the development of hepatocellular carcinoma and occult HBV infection
    Pushpinder Kaur
    International Agency for Research on Cancer, 150 cours Albert Thomas, Lyon, France
    J Infect Dis 202:700-4. 2010
    ....
  67. ncbi request reprint Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient
    Stephanie Villet
    INSERM, U271, Laboratoire des virus hépatiques et pathologies associées, Lyon F 69003, France
    J Hepatol 46:531-8. 2007
    ..Complex mutants may be selected under sequential anti-VHB pressures. We analyzed the genotypic and phenotypic evolution of the viral quasi-species of a patient who developed resistance to entecavir following lamivudine breakthrough...
  68. ncbi request reprint Rise in gamma interferon expression during resolution of duck hepatitis B virus infection
    Ramamurthy Narayan
    INSERM Unit 271, 151 Cours Albert Thomas, 69003 Lyon, France
    J Gen Virol 87:3225-32. 2006
    ....
  69. ncbi request reprint Genetic variability of hepatitis C virus in chronically infected patients with viral breakthrough during interferon-ribavirin therapy
    I Vuillermoz
    INSERM Unit 271, 151 Cours Albert Thomas, Lyon, France
    J Med Virol 74:41-53. 2004
    ..The humoral response was similar between groups. In conclusion, viral breakthrough does not seem to be due to selection of resistant strains with signature mutations...
  70. ncbi request reprint Progress in DNA vaccine for prophylaxis and therapy of hepatitis B
    Alexandre Thermet
    INSERM U271, 151 Cours Albert Thomas, 69003, Lyon, France
    Vaccine 21:659-62. 2003
    ..Therefore, DNA-based vaccine appears as a promising new approach for prophylaxis and therapy of hepatitis B...
  71. ncbi request reprint Resistance of human hepatitis B virus to reverse transcriptase inhibitors: from genotypic to phenotypic testing
    David Durantel
    INSERM Unit 271, 151 Cours Albert Thomas, 69424 Lyon Cedex 03, France
    J Clin Virol 34:S34-43. 2005
    ..These assays are described and their potential use in the clinical setting is discussed...
  72. ncbi request reprint Sustained HBs seroconversion during lamivudine and adefovir dipivoxil combination therapy for lamivudine failure
    Marianne Maynard
    Liver Department, Hotel Dieu, Lyon, France
    J Hepatol 42:279-81. 2005
    ..This report suggests that in patients who previously failed lamivudine therapy, proactive antiviral treatment may lead to a beneficial virological and clinical effect...
  73. doi request reprint Factors associated with pandemic influenza A/H1N1 vaccine coverage in a French cohort of HIV-infected patients
    L Cotte
    Hospices Civils de Lyon, hôpital de l Hôtel dieu, Service d Hepatologie, 1 Place de l Hopital, 69002 Lyon, France
    Vaccine 29:5638-44. 2011
    ..A mass influenza A/H1N1 vaccination campaign took place in France during the 2009 winter. Overall, 7.9% of the general population was vaccinated. However, vaccine coverage data are missing for at-risk groups...
  74. doi request reprint [HBsAg quantification: virological significance]
    N Ben Slama
    Hospices Civils de Lyon, Hotel Dieu, Service d hépatologie et de gastroentérologie, Lyon, France
    Gastroenterol Clin Biol 34:S112-8. 2010
    ..To fulfill this objective, prospective studies are still warranted for the the spread of sensitive and standardized techniques standardization of the quantification assays and to define cut off values with clinical predictive values...
  75. doi request reprint Long-term results of liver transplantation for Wilson's disease
    V Pabon
    Centre de Référence Maladies Rares Maladie de Wilson, Hospices Civils de Lyon, Lyon, France
    Gastroenterol Clin Biol 32:378-81. 2008
    ..For patients with severe disease, liver transplantation is the treatment of choice. The aim of this study was to report the long-term outcome of patients who underwent liver transplantation for Wilson's disease...
  76. doi request reprint [Treatment of hepatitis B: new perspectives]
    C Trepo
    INSERM, U871, Universite de Lyon, IFR62 Lyon Est, 69372 Lyon Cedex 08, France
    Gastroenterol Clin Biol 33:811-7. 2009
    ..The development of true combination therapy is highly desirable to fulfil the objective of long-term viral suppression, clearance of viral cccDNA and infected cells and ultimately cure of the disease...
  77. ncbi request reprint Learning from HIV: how will drug resistance influence treatment strategies against hepatitis C?
    David Durantel
    Molecular Physiopathology and New Treatments for Hepatitis Viruses, INSERM, U871, Lyon, France
    J HIV Ther 12:88-91. 2007
  78. ncbi request reprint Quantification and genotyping in management of chronic hepatitis B and C
    Fabien Zoulim
    INSERM U271 and Liver Unit Hotel Dieu Hospital, Lyon, France
    Virus Res 82:45-52. 2002
  79. ncbi request reprint A preliminary benefit-risk assessment of lamivudine for the treatment of chronic hepatitis B virus infection
    Fabien Zoulim
    INSERM Unit 271, Lyon, France
    Drug Saf 25:497-510. 2002
    ..For each patient, its indication has to be weighed against the risk of developing viral resistance but also against the risk of natural history of the disease...
  80. doi request reprint Hepatitis B virus replication in primary macaque hepatocytes: crossing the species barrier toward a new small primate model
    Julie Lucifora
    INSERM Unité 871, Institut National de la Sante et de la Recherche Medicale, Lyon, France
    Hepatology 51:1954-60. 2010
    ..We then demonstrated the antiviral effects of both TLR9-induced cytokines and nucleoside analogue (lamivudine) on HBV replication in transduced PMHs...
  81. ncbi request reprint Effects of liver growth factors on hepadnavirus replication in chronically infected duck hepatocytes
    Olivier Schorr
    INSERM Unit 271, 151 Cours Albert Thomas, 69003 Lyon, France
    J Hepatol 44:842-7. 2006
    ..Duck hepatitis B virus (DHBV) replication is up-regulated by cell cycle during the early infection of primary duck but the effect of cell cycle on DHBV replication in chronically infected hepatocyte is not known...
  82. doi request reprint Hepatitis B virus resistance to nucleos(t)ide analogues
    Fabien Zoulim
    INSERM, U871, Lyon, France
    Gastroenterology 137:1593-608.e1-2. 2009
    ....
  83. doi request reprint Adefovir dipivoxil is effective for the treatment of cirrhotic patients with lamivudine failure
    Fabien Zoulim
    INSERM, U871, Lyon, France
    Liver Int 29:420-6. 2009
    ..This retrospective cohort study evaluated the safety and efficacy of ADV in this specific patient population...
  84. doi request reprint Management of patients with decompensated hepatitis B virus associated [corrected] cirrhosis
    Fabien Zoulim
    INSERM, corrected U871 Lyon, France
    Liver Transpl 14:S1-7. 2008
    ..These improved strategies should enhance treatment success enough to obtain clinical stabilization, to delay or prevent the need for transplantation, and to reduce the risk of hepatitis B virus recurrence on the graft.AASLD...
  85. ncbi request reprint Duck hepatitis B virus model in the study of hepatitis B virus
    Lucyna Cova
    INSERM U271, Lyon, France
    Methods Mol Med 96:261-8. 2004
  86. doi request reprint Drug-resistant and immune-escape HBV mutants in HIV-infected hosts
    Karine Lacombe
    INSERM, UMR S707, Paris, France
    Antivir Ther 15:493-7. 2010
    ..For patients coinfected with HIV, hepatitis B treatment options that aim to reduce the risk of HBV mutations from emerging must be seriously considered, not only from clinical but also public health perspectives...
  87. ncbi request reprint [Current data on the treatment of chronic hepatitis B]
    Fabien Zoulim
    Service d Hepatogastroenterologie, Hotel Dieu, F 69002 Lyon, France
    Presse Med 37:287-93. 2008
    ..The development of these different treatment options has made possible very significant improvements in the management of patients with chronic hepatitis B, by preventing aggravation of liver disease in most of them...
  88. doi request reprint Management and prevention of drug resistance in chronic hepatitis B
    Fabien Zoulim
    INSERM, U871, Lyon, France
    Liver Int 29:108-15. 2009
    ..The future perspectives are to design strategies to hasten the HBsAg clearance, which should become a new treatment endpoint, to prevent drug resistance and to decrease the incidence of complications of chronic hepatitis B...
  89. ncbi request reprint Cloning and expression of surface antigens from occult chronic hepatitis B virus infections and their recognition by commercial detection assays
    Damien Jeantet
    U271 INSERM, Lyon, France
    J Med Virol 73:508-15. 2004
    ..Most of the isolates fall into the second category. Mutations can therefore contribute to HBsAg seronegativity in occult HBV infections, but in most cases the explanation is probably the low level of viral replication...
  90. ncbi request reprint [Study of the antiviral mechanism of action of ribavirin in the bovine viral diarrhea virus model]
    Vanessa Escuret
    INSERM U271, Virus des Hépatites et Pathologies Associées, 151, cours Albert Thomas, 69424 Lyon Cedex 03, France
    Gastroenterol Clin Biol 26:584-90. 2002
    ..Due to the absence of a cell culture model for HCV, this study evaluated the hypothesis of lethal mutagenic activity of the guanosin analogue ribavirin in HCV, using the BVDV model...
  91. ncbi request reprint Impact of highly active antiretroviral therapy (HAART) on the natural history of hepatitis B virus (HBV) and HIV coinfection: relationship between prolonged efficacy of HAART and HBV surface and early antigen seroconversion
    Patrick Miailhes
    Hotel Dieu, Service d hépatologie et de gastroentérologie, Lyon, France
    Clin Infect Dis 45:624-32. 2007
    ....
  92. pmc Hepatitis B virus resistance to antiviral drugs: where are we going?
    Fabien Zoulim
    INSERM, U871, Lyon, France Université de Lyon, 69001 Lyon, France
    Liver Int 31:111-6. 2011
    ....
  93. ncbi request reprint Assessing hepatitis B virus resistance in vitro and molecular mechanisms of nucleoside resistance
    Fabien Zoulim
    Institut Universitaire de France, Lyon, France
    Semin Liver Dis 22:23-31. 2002
    ....
  94. ncbi request reprint Current management strategies for hepatitis B in the elderly
    P Merle
    , Lyon, France
    Drugs Aging 18:725-35. 2001
    ..Besides mass HBV vaccination programmes, people sharing a house with patients infected with HBV should be vaccinated to prevent viral transmission...
  95. doi request reprint Treatment of human immunodeficiency virus and hepatitis B virus infections
    F Zoulim
    Hepatology Department, Hospices Civils de Lyon, University of Lyon, INSERM U1052, Lyon, France
    Haemophilia 18:34-7. 2012
    ..Although many of the clinical studies are initially undertaken in non-haemophilia individuals, consideration needs to be given as to the possible benefits of including those with haemophilia in the clinical assessment...
  96. doi request reprint [Results of a satisfaction survey carried out among patients living with the virus of human immunodeficiency (HIV) following therapeutic education sessions]
    C Feutrier
    Pharmacie, Groupement Hospitalier Nord, Antenne Hôtel Dieu, Hospices Civils de Lyon, 1 Place de l Hopital, 69288 Lyon Cedex 02, France
    Ann Pharm Fr 68:306-17. 2010
    ..Our goal was to identify their needs thanks to the analysis of questionnaires in order to improve their care...
  97. ncbi request reprint A new strategy for studying in vitro the drug susceptibility of clinical isolates of human hepatitis B virus
    David Durantel
    INSERM U271, Laboratoire des virus hépatiques et pathologies associées, Lyon, France
    Hepatology 40:855-64. 2004
    ..This assay should allow a better monitoring of patients undergoing antiviral therapy, as well as the screening of novel drugs on emerging resistant strains...
  98. doi request reprint In vitro characterization of viral fitness of therapy-resistant hepatitis B variants
    Stephanie Villet
    INSERM, U871, Lyon, France
    Gastroenterology 136:168-176.e2. 2009
    ....
  99. pmc Novel alpha interferon (IFN-alpha) variant with improved inhibitory activity against hepatitis C virus genotype 1 replication compared to IFN-alpha2b therapy in a subgenomic replicon system
    Vanessa Escuret
    INSERM, U271, Laboratoire des virus hépatiques et pathologies associées, 151 Cours Albert Thomas, Lyon, France
    Antimicrob Agents Chemother 50:3984-91. 2006
    ..1 could be a potent "next generation" IFN for the treatment of HCV infection, especially in nonresponders or relapsing patients infected with HCV genotype 1 who currently represent a clinical unmet need...
  100. doi request reprint Hepatitis B: reflections on the current approach to antiviral therapy
    Fabien Zoulim
    INSERM, U871, 69003 Lyon, France Université Lyon 1, IFR62 Lyon Est, 69008 Lyon, France
    J Hepatol 48:S2-19. 2008
    ..While great progress has been made in treating hepatitis B, many important issues require further study...
  101. ncbi request reprint Reduction of the infectivity of hepatitis C virus pseudoparticles by incorporation of misfolded glycoproteins induced by glucosidase inhibitors
    Cynthia Chapel
    INSERM, U871, Universite Lyon 1, et IFR62 Laennec, Lyon, France
    J Gen Virol 88:1133-43. 2007
    ..These properties suggest the potential usefulness of DNJ derivatives in combating HCV infection...